Previous Article | Next Article ![]()
J. Virol., Nov 1996, 7510-7516, Vol 70, No. 11
K Zingler and JA Young
Previously, mutant Tva receptors were classified as either partially or
completely defective in mediating subgroup A avian leukosis and sarcoma
virus (ALSV-A) entry (C. Belanger, K. Zingler, and J. A. T. Young, J.
Virol. 69:1019-1024, 1995; K. Zingler, C. Belanger, R. Peters, D. Agard,
and J. A. T. Young, J. Virol. 69:4261-4266, 1995). To specifically test the
abilities of these mutant Tva proteins to bind ALSV-A surface (SU) protein,
binding studies were performed with a subgroup A SU-immunoadhesin. This
fusion protein is composed of the subgroup A Schmidt-Ruppin SU protein
fused in frame to a rabbit immunoglobulin constant region. This reagent was
conjugated to fluorescein isothiocyanate and used for flow cytometric
analysis with transfected human 293 cells expressing different forms of
Tva. The SU- immunoadhesin bound the wild-type Tva protein with a KD of
approximately 1.5 nM. Amino acid substitutions that reduced viral entry at
Asp-46 and at Cys-35 and Cys-50, which are predicted to form an intrachain
disulfide bond in Tva, drastically reduced the binding affinity for the
SU-immunoadhesin. Thus, the effects on viral entry of some mutations could
be explained solely by changes in the binding affinity for ALSV-A SU.
However, this was not true for other mutations tested, especially those
with amino acid substitutions that replaced Trp-48. Compared with the
wild-type receptor, these latter mutations led to approximately 43- to
200-fold reductions in viral infectivity but only to approximately 2.5- to
3.4-fold reductions in the binding affinity for the SU-immunoadhesin. These
results support a role for Trp- 48 of Tva in mediating steps of viral entry
subsequent to binding ALSV- A SU.
Copyright © 1996, American Society for Microbiology
Residue Trp-48 of Tva is critical for viral entry but not for high- affinity binding to the SU glycoprotein of subgroup A avian leukosis and sarcoma viruses
Department of Microbiology and Immunology, University of California School of Medicine, San Francisco 94143, USA.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|